Pfizer Inc. on Tuesday maintained its annual sales forecast for its COVID-19 antiviral pill Paxlovid and its vaccines, as it faces lukewarm demand.
The company said it expects $22 billion in sales from Paxlovid this year. She also reiterated her forecast of $32 billion in sales of the vaccine she developed with BioNTech.
At the request of the US Securities and Exchange Commission, several pharmaceutical companies have adjusted their forecasts to include expenditures related to milestone payments and acquisitions.
The company said it now expects adjusted earnings of $6.25-6.45 per share for the full year, below its previous guidance of $6.35-6.55, mainly due to due to the impact of these expenses. (Reporting by Manas Mishra Bengaluru; Editing by Saumyadeb Chakrabarty)